Polyphosphoester nanoparticles as biodegradable platform for delivery of multiple drugs and siRNA

Drug Design, Development and Therapy

Volumn 11, Issue , 2017, Pages 483-496

  Elzeny, Hadeel ^a   Zhang, Fuwu ^b   Ali, Esraa N ^a   Fathi, Heba A ^a   Zhang, Shiyi ^c   Li, Richen ^b   El Mokhtar, Mohamed A ^d   Hamad, Mostafa A ^d   Wooley, Karen L ^b   Elsabahy, Mahmoud ^a,b,e,f  

^a ASSIUT UNIVERSITY   (Egypt)

^b TEXAS A AND M UNIVERSITY   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d Assiut University Faculty of Medicine   (Egypt)

^e Assiut University   (Egypt)

^f MISR UNIVERSITY FOR SCIENCE AND TECHNOLOGY   (Egypt)

Author keywords

Biodegradable nanoparticles; Chitosan; Paclitaxel; Polyethylenimine; Polyphosphoester; SiRNA; Sorafenib

Indexed keywords

NANOPARTICLE; PACLITAXEL; POLYETHYLENEIMINE; POLYMER; POLYPHOSPHOESTER; SMALL INTERFERING RNA; SORAFENIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; ORGANOPHOSPHORUS COMPOUND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; FREEZE DRYING; HEMOLYSIS; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LD50; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRECIPITATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INJECTIONS, INTRAVENOUS; MICE; MOLECULAR STRUCTURE; NANOPARTICLES; NIACINAMIDE; ORGANOPHOSPHORUS COMPOUNDS; PACLITAXEL; PHENYLUREA COMPOUNDS; POLYMERS; RNA, SMALL INTERFERING; STRUCTURE-ACTIVITY RELATIONSHIP; SURVIVAL RATE;

EID: 85014119893     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S128503     Document Type: Article

References (53)

1. Elsabahy M, Heo GS, Lim SM, Sun G, Wooley KL. Polymeric nanostructures for imaging and therapy. Chem Rev. 2015;115(19): 10967–11011.
2. Elsabahy M, Wooley KL. Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev. 2013;42(12):5552–5576.
3. Elsabahy M, Wooley KL. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev. 2012;41(7):2545–2561.
4. Chen Y, Wu JJ, Huang L. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther. 2010;18(4):828–834.
5. Xiong XB, Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano. 2011;5(6):5202–5213.
6. Reddy TL, Garikapati KR, Reddy SG, et al. Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma. Sci Rep. 2016;6:35223.
7. Sun TM, Du JZ, Yao YD, et al. Simultaneous delivery of siRNA and paclitaxel via a “two-in-one” micelleplex promotes synergistic tumor suppression. ACS Nano. 2011;5(2):1483–1494.
8. Chen AM, Zhang M, Wei D, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small. 2009; 5(23):2673–2677.
9. Elsabahy M, Shrestha R, Clark C, Taylor S, Leonard J, Wooley KL. Multifunctional hierarchically assembled nanostructures as complex stage-wise dual-delivery systems for coincidental yet differential trafficking of siRNA and paclitaxel. Nano Lett. 2013;13(5): 2172–2181.
10. Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer. 2004;90(2):304–305.
11. Al-Rajabi R, Patel S, Ketchum NS, et al. Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction. J Gastrointest Oncol. 2015;6(3):259–267.
12. Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2015;141(5): 861–876.
13. Kuo TC, Lu HP, Chao CC. The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. Biochem Pharmacol. 2011;82(2):184–194.
14. Dal Lago L, D’Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist. 2008;13(8):845–858.
15. Liu C, Chen Z, Chen Y, et al. Improving oral bioavailability of sorafenib by optimizing the “Spring” and “Parachute” based on molecular interaction mechanisms. Mol Pharm. 2016;13(2):599–608.
16. Wang XQ, Fan JM, Liu YO, Zhao B, Jia ZR, Zhang Q. Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. Int J Pharm. 2011; 419(1–2):339–346.
17. Raskopf E, Vogt A, Sauerbruch T, Schmitz V. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol. 2008;49(6):977–984.
18. Bogorad RL, Yin H, Zeigerer A, et al. Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice. Nat Commun. 2014;5:3869.
19. Elsabahy M, Nazarali A, Foldvari M. Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv. 2011;8(3): 235–244.
20. Mohamed NK, Hamad MA, Hafez MZ, Wooley KL, Elsabahy M. Nanomedicine in management of hepatocellular carcinoma: challenges and opportunities. Int J Cancer. Epub 2016 Nov 15.
21. Zhang S, Zou J, Zhang F, et al. Rapid and versatile construction of diverse and functional nanostructures derived from a polyphosphoester-based biomimetic block copolymer system. J Am Chem Soc. 2012;134(44): 18467–18474.
22. Elsabahy M, Zhang S, Zhang F, et al. Surface charges and shell cross-links each play significant roles in mediating degradation, biofouling, cytotoxicity and immunotoxicity for polyphosphoester-based nanoparticles. Sci Rep. 2013;3:3313.
23. Mao CQ, Du JZ, Sun TM, et al. A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy. Biomaterials. 2011;32(11):3124–3133.
24. Wang HX, Xiong MH, Wang YC, Zhu J, Wang J. N-acetylgalactosamine functionalized mixed micellar nanoparticles for targeted delivery of siRNA to liver. J Control Release. 2013;166(2):106–114.
25. Zhang F, Zhang S, Pollack SF, et al. Improving paclitaxel delivery: in vitro and in vivo characterization of PEGylated polyphosphoester-based nanocarriers. J Am Chem Soc. 2015;137(5):2056–2066.
26. Morsi NG, Ali SM, Elsonbaty SS, et al. Poly(glycerol methacrylate)-based degradable nanoparticles for delivery of small interfering RNA. Pharm Dev Technol. In press 2017.
27. DePass LR. Alternative approaches in median lethality (LD50) and acute toxicity testing. Toxicol lett. 1989;49(2–3):159–170.
28. Van den Heuvel MJ, Clark DG, Fielder RJ, et al. The international validation of a fixed-dose procedure as an alternative to the classical LD50 test. Food Chem Toxicol. 1990;28(7):469–482.
29. Miller LC, Tainter M. Estimation of the ED50 and its error by means of logarithmic-probit graph paper. Exp Biol Med. 1944;57(2):261–264.
30. Haroon MM, Dar GH, Jeyalakshmi D, et al. A designed recombinant fusion protein for targeted delivery of siRNA to the mouse brain. J Control Release. 2016;228:120–131.
31. Sato Y, Note Y, Maeki M, et al. Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery. J Control Release. 2016;229:48–57.
32. Zhang F, Smolen JA, Zhang S, et al. Degradable polyphosphoester-based silver-loaded nanoparticles as therapeutics for bacterial lung infections. Nanoscale. 2015;7(6):2265–2270.
33. Liu JY, Huang W, Pang Y, Zhu X, Zhou Y, Yan D. The in vitro biocompatibility of self-assembled hyperbranched copolyphosphate nanocarriers. Biomaterials. 2010;31(21):5643–5651.
34. Zou J, Zhang F, Zhang S, et al. Poly(ethylene oxide)-block-polyphosphoester-graft-paclitaxel conjugates with acid-labile linkages as a pH-sensitive and functional nanoscopic platform for paclitaxel delivery. Adv Healthc Mater. 2014;3(3):441–448.
35. Li A, Luehmann HP, Sun G, et al. Synthesis and in vivo pharmacokinetic evaluation of degradable shell cross-linked polymer nanoparticles with poly(carboxybetaine) versus poly(ethylene glycol) surface-grafted coatings. ACS Nano. 2012;6(10):8970–8982.
36. Chen CK, Jones CH, Mistriotis P, et al. Poly(ethylene glycol)-block-cationic polylactide nanocomplexes of differing charge density for gene delivery. Biomaterials. 2013;34(37):9688–9699.
37. Quadir MA, Morton SW, Deng ZJ, et al. PEG-polypeptide block copolymers as pH-responsive endosome-solubilizing drug nanocarriers. Mol Pharm. 2014;11(7):2420–2430.
38. He X, Fan J, Zhang F, et al. Multi-responsive hydrogels derived from the self-assembly of tethered allyl-functionalized racemic oligopeptides. J Mater Chem B Mater Biol Med. 2014;2(46):8123–8130.
39. Sun CY, Dou S, Du JZ, Yang XZ, Li YP, Wang J. Doxorubicin conjugate of poly(ethylene glycol)-block-polyphosphoester for cancer therapy. Adv Healthc Mater. 2014;3(2):261–272.
40. Sun TM, Du JZ, Yan LF, Mao HQ, Wang J. Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery. Biomaterials. 2008;29(32):4348–4355.
41. Elsabahy M, Dufresne MH, Leroux JC. Polymeric micelles as versatile carriers for drugs and nucleic acids delivery. In: Torchilin V, Amiji M, editors. Materials for Nanomedicine. Hackensack, NY: Pan Stanford Publishing; 2010:169–234.
42. Zhang S, Zou J, Elsabahy M, et al. Poly(ethylene oxide)-block-polyphosphester-based paclitaxel conjugates as a platform for ultra-high paclitaxel-loaded multifunctional nanoparticles. Chem Sci. 2013;4(5):2122–2126.
43. Elsabahy M, Zhang M, Gan SM, Waldron KC, Leroux JC. Synthesis and enzymatic stability of PEGylated oligonucleotide duplexes and their self-assemblies with polyamidoamine dendrimers. Soft Matter. 2008; 4(2):294–302.
44. Wen J, Mao HQ, Li W, Lin KY, Leong KW. Biodegradable polyphosphoester micelles for gene delivery. J Pharm Sci. 2004;93(8): 2142–2157.
45. Elsabahy M, Wazen N, Puxan N, et al. Delivery of nucleic acids through the controlled disassembly of multifunctional nanocomplexes. Adv Funct Mater. 2009;19(24):3862–3867.
46. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91(19):1616–1634.
47. Lu J, Chuan X, Zhang H, et al. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo. Int J Pharm. 2014;471(1–2):525–535.
48. Kim DH, Kim MD, Choi CW, et al. Antitumor activity of sorafenib-incorporated nanoparticles of dextran/poly(dl-lactide-co-glycolide) block copolymer. Nanoscale Res Lett. 2012;7(1):91.
49. Morisaki T, Umebayashi M, Kiyota A, et al. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro. Anticancer Res. 2013;33(4):1387–1395.
50. Chen W, Wu J, Shi H, et al. Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/ Stat3 pathways. Biomed Res Int. 2014;2014:764981.
51. Elsabahy M, Wooley KL. Data mining as a guide for the construction of cross-linked nanoparticles with low immunotoxicity via control of polymer chemistry and supramolecular assembly. Acc Chem Res. 2015; 48(6):1620–1630.
52. Elsabahy M, Samarajeewa S, Raymond JE, Clark C, Wooley KL. Shell-crosslinked knedel-like nanoparticles induce lower immunotoxicity than their non-crosslinked analogs. J Mater Chem B Mater Biol Med. 2013;1(39):5241–5255.
53. Harada-Shiba M, Yamauchi K, Harada A, Takamisawa I, Shimokado K, Kataoka K. Polyion complex micelles as vectors in gene therapy– pharmacokinetics and in vivo gene transfer. Gene Ther. 2002;9(6): 407–414.